Pericardial effusion requiring intervention in patients undergoing percutaneous left atrial appendage occlusion: Prevalence, predictors, and associated in-hospital adverse events from 17,700 procedures in the United States

Muhammad Bilal Munir, MD,* Muhammad Zia Khan, MD,† Douglas Darden, MD,* Deepak Kumar Pasupula, MD,‡ Sudarshan Balla, MD,† Frederick T. Han, MD, FHRS,* Ryan Reeves, MD,* Jonathan C. Hsu, MD, MAS, FHRS*

From the *Section of Electrophysiology, Division of Cardiology, University of California San Diego, La Jolla, California, †Division of Cardiovascular Medicine, West Virginia University Heart & Vascular Institute, Morgantown, West Virginia, and ‡Division of Cardiology, Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

BACKGROUND Left atrial appendage occlusion has shown promise in mitigating the risk of stroke in selected patients with atrial fibrillation.

OBJECTIVE The purpose of this study was to determine the real-world prevalence and in-hospital outcomes in left atrial appendage occlusion (Watchman) recipients complicated by pericardial effusion requiring percutaneous drainage or open cardiac surgery-based intervention.

METHODS Data were derived from the National Inpatient Sample database from January 2015 to December 2017. The primary outcomes assessed were the prevalence of pericardial effusion requiring intervention and in-hospital outcomes including mortality, other major complications, hospital stay > 1 day, and hospitalization costs. Predictors of pericardial effusion requiring intervention were also analyzed.

RESULTS Pericardial effusion requiring intervention occurred in 220 total patients (1.24%). After multivariable adjustment, pericardial effusion requiring intervention was associated with in-hospital mortality (adjusted odds ratio [aOR] 51.16; 95% confidence interval [CI] 12.56–214.77), length of stay > 1 day (aOR 17.64; 95% CI 12.56–24.77), and hospitalization cost above the median of $24,327 (aOR 3.58; 95% CI 2.61–4.91). Independent patient predictors of pericardial effusion requiring intervention from the procedure included advanced age (aOR 1.029 per 1-year increase; 95% CI 1.009–1.05 per 1-year increase), higher CHA2DS2-VASc score (aOR 1.109–1.07 per 1-point increase; 95% CI 1.083–1.377 per 1-point increase), and obesity (aOR 2.033; 95% CI 1.464–2.823).

CONCLUSION In a large, contemporary real-world cohort of Watchman recipients in US practice, the prevalence of pericardial effusion requiring intervention was 1.24%. Pericardial effusion requiring intervention was associated with several adverse events including increased in-hospital mortality, other major complications, prolonged hospital stay, and hospitalization costs.

KEYWORDS Complications; Mortality; National estimates; Pericardial effusion; Watchman

Introduction

Atrial fibrillation (AF) is an important cause of cardioembolic stroke as it results in thrombus formation in the left atrial appendage (LAA) in >90% of patients.1 Although coumadin and direct oral anticoagulants are effective in reducing AF-associated stroke risk, their use is limited by patient compliance and adverse effects.2–4 LAA occlusion using a Watchman device (Boston Scientific, MA) has shown...
promising results as an alternative to stroke risk reduction in selected patients with AF. The landmark PROTECT AF (percutaneous closure of the left atrial appendage vs warfarin therapy for prevention of stroke in patients with atrial fibrillation) trial showed Watchman implantation to be noninferior to coumadin with respect to the primary composite end point of stroke, systemic embolism, and cardiovascular death. However, a periprocedural safety hazard was identified in this trial as close to 5% of patients sustained serious pericardial effusion requiring percutaneous drainage or open cardiac surgery–based intervention. Subsequent studies such as PREVAIL (prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation vs long-term warfarin therapy) trial and CAP (continued access to PROTECT AF) registry showed reduction in rates for serious pericardial effusion.6,7

As one of the most feared complications from an LAA occlusion procedure, pericardial effusion requiring intervention from LAA occlusion is assumed to be associated with significant morbidity and mortality; however, this association and its magnitude have not been studied in a large population of Watchman recipients. There are also limited real-world data on the prevalence of pericardial effusion requiring percutaneous drainage or open cardiac surgery–based intervention in patients implanted with a Watchman device outside of controlled clinical trials. Furthermore, patient-level predictors of pericardial effusion requiring intervention have not been identified and may provide insight into who may be most at risk. We aimed to study these parameters from a nationally representative US population sample.

Methods
For the purpose of the present analysis, data were derived from the National Inpatient Sample (NIS) for calendar years 2015–2017. The year 2015 was taken as a starting year for our analysis since the Watchman device was approved by the Food and Drug Administration in that year. The NIS is made possible by a Federal–state–industry partnership sponsored by the Agency for Healthcare Research and Quality. The NIS is derived from all states for national estimates of health care utilization, costs, and outcomes. NIS data are compiled annually, and therefore data can be used for analyses of disease trends over time. The NIS approximates 20% of all discharges from all US non-Federal hospitals and provides discharge weights that are used for the computation of national estimates. Institutional review board approval and informed consents were not required for this study given the de-identified nature of the NIS data set and public availability. The NIS adheres to the 2013 Declaration of Helsinki for conduction of human research.

We identified patients undergoing Watchman implantation using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes of 37.90 and 02L73DK, respectively. Patients younger than 18 years were excluded. The study population was then divided into patients who sustained pericardial effusion requiring percutaneous drainage or open cardiac surgery–based intervention and those patients who did not have this complication. For percutaneous drainage, the ICD-9-CM code of 37.0 and ICD-10-CM codes of 0W9D30Z and 0W9D3ZZ were used. For the open cardiac surgery–based intervention, the ICD-9-CM code of 37.1 and ICD-10-CM codes of 0W9D00Z and 0W9D0ZZ were used. Baseline characteristics, in-hospital outcomes, and key complications were compared in Watchman recipients on the basis of the presence or absence of pericardial effusion requiring percutaneous drainage or open cardiac surgery–based intervention. For computing hospitalization costs, the cost-to-charge ratio files supplied by the Healthcare Cost and Utilization Project were applied to the total hospital charges and adjusted for inflation to December 2017. Independent associations of pericardial effusion requiring intervention (vs not) with in-hospital mortality, major complications (defined as composite of cardiac arrest, myocardial infarction, ischemic stroke, hemorrhagic stroke, transient ischemic attack, major bleeding, and vascular complication), length of stay > 1 day, and hospitalization cost above the median of $24,327 were analyzed. Additionally, the independent associations of pericardial effusion requiring open cardiac surgery–based intervention vs percutaneous drainage with in-hospital mortality, major complications, length of stay > 1 day, and hospitalization cost above the median of $24,327 were analyzed. We also assessed patient-level predictors of pericardial effusion requiring intervention in our study cohort.

Descriptive statistics are presented as frequency with percentage for categorical variables and as median with interquartile range (IQR) for continuous variables. Baseline characteristics were compared using the Pearson $X^2$ test and Fisher exact test for categorical variables and the Mann-Whitney U test for continuous variables. Logistic regression was performed to estimate odds ratios (ORs) with 95% confidence intervals (CIs) to determine patient-level predictors of pericardial effusion requiring percutaneous drainage or open cardiac surgery–based intervention. A forward stepwise entry model was used for this purpose. Initially, all variables, which were significantly associated with pericardial effusion with a $P$ value of <.05 in univariable analysis, were entered into the model from the baseline table. Subsequently, only those variables were retained in the model that were associated with pericardial effusion with a $P$ value of <.10 during forward entry. For the assessment of the independent association of pericardial effusion requiring intervention with key outcomes including in-hospital mortality, other major complication, length of stay $>1$ day, and hospitalization cost above the median of $24,327, a single-step multivariable-adjusted regression model was used. Age, sex, race/ethnicity, CHA2DS2-VASc score, hospital bed size, and standard comorbidities were used to adjust the model. A type I error rate of <.05 was
Table 1  Baseline characteristics of the study population of Watchman recipients stratified on the basis of having pericardial effusion requiring intervention vs not

| Variable                        | Pericardial effusion requiring intervention (n = 220) | No pericardial effusion requiring intervention (n = 17,480) | P     |
|---------------------------------|------------------------------------------------------|------------------------------------------------------------|-------|
| Age (y)                         | 78.5 (72.5–82.75)                                      | 76 (71–82)                                                 | <.001 |
| Female sex                      | 135 (61.4)                                             | 6,960 (39.8)                                               | <.001 |
| Race/ethnicity                  |                                                      |                                                           |       |
| White                           | 185 (84.1)                                             | 14,465 (86.1)                                             | <.001 |
| Black                           | <10 (<2.3)                                             | 690 (4.1)                                                  |       |
| Hispanics                        | <10 (<2.3)                                             | 925 (5.5)                                                  |       |
| Others                          | 25 (11.4)                                              | 725 (4.3)                                                  |       |
| CHA2DS2-VASc score              |                                                      |                                                           |       |
| 2                               | 35 (15.9)                                              | 2,740 (15.7)                                              | <.001 |
| 3                               | 50 (22.7)                                              | 5,730 (32.8)                                              | <.001 |
| 4                               | 70 (31.8)                                              | 5,240 (30)                                                | <.001 |
| 5                               | 40 (18.2)                                              | 2,200 (12.6)                                              | <.001 |
| ≥6                              | 15 (7.8)                                               | 860 (4.9)                                                  |       |
| Median score                    | 4 (3–4.75)                                             | 3 (3–4)                                                   | .016  |
| Comorbidities                   |                                                      |                                                           |       |
| Deficiency anemia               | 40 (18.2)                                              | 2,410 (13.8)                                              | <.001 |
| Congestive heart failure        | 75 (34.1)                                              | 5,665 (32.4)                                              | <.001 |
| Chronic pulmonary disease       | 40 (18.2)                                              | 3,715 (21.3)                                              | <.001 |
| Coagulopathy                    | 20 (9.1)                                               | 840 (4.8)                                                  | <.001 |
| Cerebrovascular disease         | <10 (<4)                                               | 1,380 (7.9)                                                | <.001 |
| Diabetes                        | 30 (13.6)                                              | 3,745 (21.4)                                              | <.001 |
| Diabetes with complications     | 35 (15.9)                                              | 2,145 (13.3)                                              | <.001 |
| Hypertension                    | 115 (52.3)                                             | 11,165 (63.9)                                             | <.001 |
| Alcohol abuse                   | 40 (18.1)                                              | 791 (4.5)                                                  | <.001 |
| Liver disease                   | <10 (<2.3)                                             | 430 (2.5)                                                  | <.001 |
| Obesity                         | 50 (22.7)                                              | 2,655 (15.2)                                              | <.001 |
| Peripheral vascular disorders   | 30 (13.6)                                              | 1,940 (11.1)                                              | <.001 |
| Chronic kidney disease          | 35 (15.9)                                              | 3,775 (21.6)                                              | <.001 |
| Valvular disease                | 0 (0.0)                                                | 45 (0.3)                                                   | <.001 |
| Hospital location               |                                                      |                                                           |       |
| Rural                           | 0 (0.0)                                                | 215 (1.2)                                                  | <.001 |
| Urban nonteaching               | 20 (9.1)                                               | 1,750 (10.0)                                              |       |
| Urban teaching                  | 200 (90.9)                                             | 15,515 (88.8)                                             |       |
| Bed size                        |                                                      |                                                           |       |
| Small                           | 25 (11.4)                                              | 1,890 (10.8)                                              | <.001 |
| Medium                          | 60 (27.3)                                              | 3,830 (21.9)                                              |       |
| Large                           | 135 (61.4)                                             | 11,760 (67.3)                                             |       |
| Census division                 |                                                      |                                                           |       |
| New England                     | 0 (0.0)                                                | 540 (3.1)                                                  | <.001 |
| Mid-Atlantic                    | 35 (15.9)                                              | 2,250 (12.9)                                              |       |
| East North Central              | 30 (13.6)                                              | 2,410 (13.8)                                              |       |
| West North Central              | <10 (<2.3)                                             | 1,180 (6.8)                                                |       |
| South Atlantic                  | 50 (22.7)                                              | 3,790 (21.7)                                              |       |
| East South Central              | <10 (<4)                                               | 810 (4.6)                                                  |       |
| West South Central              | 40 (18.2)                                              | 2,055 (11.8)                                              |       |
| Mountain                        | 20 (9.1)                                               | 1,680 (9.6)                                                |       |
| Pacific                         | 30 (13.6)                                              | 2,765 (15.8)                                              |       |
| Payee                           |                                                      |                                                           |       |
| Medicare/Medicaid               | 205 (93.2)                                             | 15,750 (90.4)                                             | <.001 |
| Private insurance               | <10 (<4)                                               | 1,425 (8.2)                                                |       |
| Self-pay                        | 0 (0.0)                                                | 65 (0.4)                                                   |       |
| Other                           | <10 (<2.3)                                             | 185 (1.1)                                                  |       |
| Median income                   |                                                      |                                                           |       |
| 0th–25th                        | 50 (23.3)                                              | 3,480 (20.2)                                              | <.001 |
| 26th–50th                       | 50 (23.3)                                              | 4,210 (24.5)                                              |       |
| 51th–75th                       | 40 (18.6)                                              | 4,930 (28.7)                                              |       |
| 76th–100th                      | 75 (34.9)                                              | 4,575 (26.6)                                              |       |

Values are presented as median (interquartile range) or n (%).
For N < 10, the absolute numbers are not reported as per Healthcare Cost and Utilization Project recommendations.
considered statistically significant. All statistical analyses were performed using SPSS version 26 (IBM Corporation, Armonk, NY) and R version 3.6. Because of the complex survey design of the NIS, sample weights, strata, and clusters were applied to the raw data to generate national estimates.

Results
From January 2015 to December 2017, a total of 17,700 patients were implanted with a Watchman LAA occlusion device. Pericardial effusion requiring percutaneous drainage or open cardiac surgery–based intervention occurred in 220 total patients (1.24%). The baseline characteristics of the study population stratified on the basis of pericardial effusion requiring intervention (vs not) are summarized in Table 1. The prevalence of pericardial effusion requiring intervention was more in female patients undergoing Watchman implantation (61.4% vs 39.8%; P < .001). Patients with a CHA$_2$DS$_2$-VASc score of 5 and 6 or more were generally more prone to the development of pericardial effusion requiring intervention (18.2% vs 12.6%; P < .001 and 7.8% vs 4.9%; P < .001, respectively). Comorbidities such as deficiency anemia (18.2% vs 13.8%; P < .001), coagulopathy (9.1% vs 4.8%; P < .001), congestive heart failure (34.1% vs 32.4%; P < .001), obesity (22.7% vs 15.2%; P < .001), and complicated diabetes (15.9% vs 12.3%; P < .001) were more common in patients with pericardial effusion requiring intervention.

In-hospital outcomes and important Watchman-related complications stratified on the basis of pericardial effusion requiring intervention (vs not) are presented in Tables 2 and 3, respectively. Death was more common in patients with pericardial effusion requiring intervention than in those who did not have this complication (11.4% vs 0.1%; P < .001). Patients with pericardial effusion requiring intervention had a higher prevalence of other Watchman-related complications than did patients without pericardial effusion requiring intervention (38.6% vs 9.3%; P < .001). This is primarily composed of any other cardiovascular (25% vs 2.1%; P < .001) and pulmonary (20.5% vs 2.9%; P < .001) complications, respectively. Nonhome discharges were more prevalent in the pericardial effusion requiring intervention cohort (15.4% vs 3.3%; P < .001). Patients with pericardial effusion requiring intervention were also noted to have a longer median length of stay (4 days [IQR 2–6 days] vs 1 day [IQR 1–2 days]; P < .001) and an increased total cost of hospitalization ($36,767 ± [IQR $27,846–$50,411] vs $24,275 [IQR $18,607–$30,072]; P < .001).

To assess the independent association of the complication of pericardial effusion requiring intervention with other in-hospital outcomes, we constructed multivariable models adjusting for potential confounders. After adjustment, pericardial effusion requiring intervention was independently associated with increased mortality (adjusted OR [aOR] 511.6; 95% CI 122–2145.3), increased rate of other Watchman-related major complications (aOR 1.35; 95% CI 0.83–2.19), length of stay > 1 day (aOR 17.64; 95% CI 12.56–24.77), and hospitalization cost higher than the median of $24,327 (aOR 3.58; 95% CI 2.61–4.91). Please see Figure 1 for detailed results. The independent associations of pericardial effusion requiring open cardiac surgery–based intervention vs percutaneous drainage with outcomes of in-hospital mortality, major complications, length of stay > 1 day, and hospitalization cost above the median of $24,327 are shown in Online Supplemental Figure 1. No significant differences in in-hospital mortality (aOR 2.00; 95% CI 0.25–15.67), other Watchman-related major complications (aOR 0.63; 95% CI 0.14–2.76), and length of stay > 1 day (aOR 0.62; 95% CI 0.18–2.10) were observed in patients who underwent open cardiac surgery–based intervention vs percutaneous drainage of pericardial effusion.

Patient-level characteristics that predicted pericardial effusion requiring intervention are shown in Figure 2. After multivariable adjustment, advanced age (OR 1.029 per 1-year increase; 95% CI 1.009–1.05 per 1-year increase), higher CHA$_2$DS$_2$-VASc score (OR 1.221 per 1-point increase; 95% CI 1.083–1.377 per 1-point increase), anemia (OR 2.316; 95% CI 1.428–3.755), and obesity (OR 2.033; 95% CI 1.464–2.823) were associated with a higher odds of pericardial effusion requiring intervention. Diabetes (OR 0.617; 95% CI 0.428–0.889), hypertension (OR 0.348; 95% CI 0.253–0.477), and chronic kidney disease (OR 0.51; 95% CI 0.357–0.728) were associated with a lower odds of pericardial effusion requiring intervention.

Discussion
The main findings of the present investigation are as follows: (1) In a large, contemporary, real-world cohort of patients undergoing Watchman LAA occlusion implantation, the overall

### Table 2 Hospital outcomes and resource utilization in Watchman recipients

| Outcome                              | Pericardial effusion requiring intervention (n = 220) | No pericardial effusion requiring intervention (n = 17,480) | P     |
|--------------------------------------|-----------------------------------------------------|----------------------------------------------------------|-------|
| Died at discharge                    | 25 (11.4)                                           | 20 (0.1)                                                 | <.001 |
| Discharge disposition                |                                                     |                                                          |       |
| Home/routine/self-care              | 165 (84.6)                                          | 16,880 (96.7)                                            | <.001 |
| Nonhome discharges                  | 30 (15.4)                                           | 580 (3.3)                                                |       |
| Resource utilization                |                                                     |                                                          |       |
| Length of stay (d)                  | 4 (2–6)                                             | 1 (1–1)                                                  | <.001 |
| Cost of hospitalization ($)          | 36,767 (27,846–50,411)                              | 24,275 (18,607–30,702)                                   | <.001 |

Values are presented as median (interquartile range) or n (%).
prevalence of pericardial effusion requiring percutaneous drainage or open cardiac surgery–based intervention was 1.24%. Patients undergoing Watchman implantation complicated by pericardial effusion requiring intervention (vs those who did not have this complication) had higher mortality, other Watchman-related complications, hospital length of stay, and increased hospitalization costs. Patient-level characteristics that predicted those who were at increased risk of having pericardial effusion requiring intervention included advanced age, higher CHA2DS2-VASc score, and obesity whereas a history of diabetes, hypertension, and chronic kidney disease was associated with a less risk of having pericardial effusion requiring intervention.

The landmark PROTECT AF trial demonstrated benefit of Watchman implantation with respect to stroke risk reduction in patients with AF but also showed an increased rate of periprocedural pericardial effusion requiring percutaneous drainage or open cardiac surgery–based intervention. The overall rate of serious pericardial effusion requiring intervention in the PROTECT AF trial was close to 5%. Furthermore, the incidence of pericardial effusion was significantly more in the first half of the PROTECT AF trial (6.3%) as compared with the second half of the study (3.7%). The complimentary registry to the PROTECT AF trial

| Variable | Pericardial effusion requiring intervention (n = 220) | No pericardial effusion requiring intervention (n = 17,480) | P |
|----------|---------------------------------------------------|-------------------------------------------------|---|
| Other complications | 85 (38.6) | 1625 (9.3) | <.001 |
| Major complications* | 25 (11.4) | 1085 (6.2) | <.001 |
| Cardiovascular complications | | | |
| Any cardiovascular complication | 55 (25.0) | 365 (2.1) | <.001 |
| Percutaneous coronary intervention | <10 (<4) | 25 (0.1) | <.001 |
| Cardiac arrest | <10 (<4) | <10 (<0.2) | <.001 |
| Heart block | 0 (0.0) | 190 (1.1) | .180 |
| ST-segment elevation myocardial infarction | <10 (<2.3) | 20 (0.1) | <.001 |
| Non–ST-segment elevation myocardial infarction | <10 (<2.3) | 60 (0.3) | .001 |
| Cardiogenic shock | 25 (11.4) | 40 (0.2) | <.001 |
| Systemic complications | | | |
| Any systemic complication | 0 (0.0) | 40 (0.2) | >.99 |
| Anaphylaxis | 0 (0.0) | <10 (0.0) | >.99 |
| Arterial embolism | 0 (0.0) | 25 (0.1) | >.99 |
| Septic shock | 0 (0.0) | <10 (0.1) | >.99 |
| Vascular complications | | | |
| Any peripheral vascular complication | <10 (<2.3) | 190 (1.1) | .994 |
| AV fistula | 0 (0.0) | 25 (0.1) | >.99 |
| Pseudoaneurysm | 0 (0.0) | 60 (0.3) | >.99 |
| Access site hematoma | 0 (0.0) | 40 (0.2) | >.99 |
| Retroperitoneal bleeding | 0 (0.0) | 30 (0.2) | >.99 |
| Venous thromboembolism | <10 (<2.3) | 45 (0.3) | <.001 |
| Neurological complications | | | |
| Any neurological complication | 0 (0.0) | 250 (1.4) | .080 |
| Hemorrhagic stroke | 0 (0.0) | 70 (0.4) | >.99 |
| Ischemic stroke | 0 (0.0) | 140 (0.8) | .425 |
| Transient ischemic attack | 0 (0.0) | 40 (0.2) | >.99 |
| Pulmonary complications | | | |
| Any pulmonary complications | 45 (20.5) | 500 (2.9) | <.001 |
| Respiratory failure | 25 (11.4) | 295 (1.7) | <.001 |
| Pneumothorax | 15 (6.8) | 80 (0.5) | <.001 |
| Pleural effusion | 0 (0.0) | 90 (0.5) | <.001 |
| Pneumonia | <10 (<4) | 75 (0.4) | .632 |
| Need for a prolonged ventilator (>36 h) | 20 (9.1) | 135 (0.8) | <.001 |

Values are presented as n (%).

For N < 10, the absolute numbers are not reported as per Healthcare Cost and Utilization Project recommendations.

AV = atrioventricular.

*Defined as composite of cardiac arrest, myocardial infarction, ischemic stroke, hemorrhagic stroke, transient ischemic attack, major bleeding, and vascular complication.

Mechanical LAA occlusion using a Watchman device has shown promise in reducing stroke risk associated with AF, especially in patients who are intolerant to oral anticoagulants. The landmark PROTECT AF trial demonstrated benefit of Watchman implantation with respect to stroke risk reduction in patients with AF but also showed an increased rate of periprocedural pericardial effusion requiring percutaneous drainage or open cardiac surgery–based intervention. The overall rate of serious pericardial effusion requiring intervention in the PROTECT AF trial was close to 5%. Furthermore, the incidence of pericardial effusion was significantly more in the first half of the PROTECT AF trial (6.3%) as compared with the second half of the study (3.7%). The complimentary registry to the PROTECT AF
trial (CAP registry) showed a reduced incidence of pericardial effusion requiring intervention with a reported rate of 2.2%. The incidence of pericardial effusion requiring intervention further lowered to ~2% in the PREVAIL trial. In a more recent study from the NCDR Left Atrial Appendage Occlusion Registry, the incidence of pericardial effusion requiring intervention was reported to be ~1.39%. Our real-world analysis of >17,000 Watchman recipients showed the prevalence of pericardial effusion requiring intervention to be ~1.24%, which is similar to the reported data from the NCDR Left Atrial Appendage Occlusion Registry. With the clinical availability of a new generation Watchman FLX device, the rate of pericardial effusion requiring intervention in real-world clinical practice is expected to reduce further. The Watchman FLX device was analyzed in the pivotal Protection Against Embolism for Nonvalvular AF Patients: Investigational Device Evaluation of the Watchman FLX LAA Closure Technology trial and showed no incidence of pericardial effusion requiring intervention at 7 days postimplantation.

Because of a significant number of pericardial effusions requiring intervention experienced in our cohort, it is important to understand the predictors of this event. Figure 1 shows the adjusted association of pericardial effusion requiring intervention with inpatient mortality, other major Watchman-related complications, prolonged length of stay, and increased hospitalization costs. Figure 2 illustrates patient-level predictors of pericardial effusion requiring intervention. The data points are adjusted for age, sex, race, CHA2DS2-VASc score, hospital bedsize and selected comorbid conditions.
worthwhile to assess the possible mechanisms leading to this complication during Watchman implantation. Earlier studies have demonstrated that nearly all procedural aspects of Watchman implantation have been associated with a risk of significant pericardial effusion. In a root cause analysis from the CAP registry, which encompassed a thorough review of procedural details, most pericardial effusions were related to the placement of adjunctive devices such as guidewires or catheters in the LAA (18%) and actual deployment of the Watchman device itself (18%). This was then followed by delivery system manipulation within the LAA (14%) and transseptal puncture (9%) in descending order. Increased familiarity and experience with various procedural steps involved in Watchman implantation by the operators will continue to mitigate this risk of significant pericardial effusion and subsequent mortality. Our study has highlighted certain patient-related factors such as advanced age, higher CHA2DS2-VASc score, and obesity that are associated with an increased risk of pericardial effusion requiring intervention and that can guide implanting physicians in risk stratification before the procedure. On the contrary, we have also shown that the presence of other comorbidities such as diabetes, hypertension, and chronic kidney disease were associated with a lower risk of pericardial effusion requiring intervention. The exact mechanism why these comorbidities were associated with a lower risk of significant pericardial effusion is unknown but should be the subject of future studies. The new generation Watchman FLX device has a lower profile design and a predeployment ball with protected distal struts and may be more safely manipulated in the LAA before deployment, thereby reducing the risk of traumatic perforation and resulting pericardial effusion; however, this has yet to be examined in large real-world cohorts using the new generation device.

Our study also showed increased resource utilization in patients with pericardial effusion after Watchman implantation. This is expected, as all patients needed either percutaneous drainage or open cardiac surgery–based intervention of such effusions that subsequently prolonged hospital length of stay as well as associated costs. Further reduction in the rate of clinically significant pericardial effusion will have the potential to make Watchman devices more cost effective.

Limitations
Our study has following key limitations: (1) The NIS is an administrative claims–based database that uses ICD codes, which may be prone to errors. The hard clinical end points such as mortality and pericardial effusion, however, are less subject to error. Additionally, Agency for Healthcare Research and Quality quality control measures are routinely instituted that guarantee data integrity. Furthermore, the ICD-9 code used in this study was not specific to the Watchman device and could be referred for any LAA occlusion procedure. Because of the limited magnitude of other research study of endocardial devices and any epicardial LAA occlusion procedures performed in the United States, we believe that the application of this code for the purpose of our study was able to mostly characterize Watchman implants. (2) The NIS captures only inpatient admissions and does not provide any information on outpatient encounters. This limitation may result in selection bias; however, our data are well representative of the national utilization of Watchman devices performed during inpatient settings; in fact, since inpatient hospitalization is often required for reimbursement for the procedure, our results may be more indicative of widespread practice. (3) The NIS censors data gathering at discharge, so long-term outcomes could not be ascertained from the present data set. (4) Specific data on potential confounders including medications, LAA morphology, and operator and intraprocedural characteristics could not be examined from the NIS. The NIS is also limited by the lack of more granular data on imaging modalities used to guide LAA occlusion and also does not contain information on the likely causative intraprocedural etiologies for pericardial effusion in the setting of LAA occlusion.

Conclusion
In this large real-world registry of Watchman recipients, we found the prevalence of pericardial effusion requiring percutaneous drainage or open cardiac surgery–based intervention to be 1.24%. Pericardial effusion requiring intervention was independently associated with inpatient mortality, other major Watchman-related complications, prolonged length of stay, and increased hospitalization costs.

Appendix
Supplementary data
Supplementary data associated with this article can be found in the online version at https://doi.org/10.1016/j.hrthm.2021.05.017.

References
1. Alkhouli M, Noseworthy PA, Rihal CS, Holmes DR Jr. Stroke prevention in nonvalvular atrial fibrillation: a stakeholder perspective. J Am Coll Cardiol 2018;71:2790–2801.
2. Hayden DT, Hannon N, Callaly E, et al. Rates and determinants of 5-year outcomes after atrial fibrillation-related stroke: a population study. Stroke 2015;46:3488–3493.
3. Oldgren J, Healey JS, Ezekowitz M, Commerrford P, et al. RE-LY Atrial Fibrillation Registry Investigators. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 2014;129:1568–1576.
4. Hsu JC, Maddox TM, Kennedy KF, et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE Registry. JAMA Cardiol 2016;1:55–62.
5. Holmes DR, Reddy VY, Turi ZG, et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534–542.
6. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014;64:1–12.
7. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage...
System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011;123:417–424.

8. Agency for Healthcare Research and Quality. Overview of the National (Nation-wide) Inpatient Sample (NIS). Rockville, MD: Agency for Healthcare Research and Quality. https://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed December 21, 2020.

9. Holmes DR Jr, Alkhouli M, Reddy V. Left atrial appendage occlusion for the unmet clinical needs of stroke prevention in nonvalvular atrial fibrillation. Mayo Clin Proc 2019;94:864–874.

10. Baman JR, Mansour M, Heist EK, Huang DT, Biton Y. Percutaneous left atrial appendage occlusion in the prevention of stroke in atrial fibrillation: a systematic review. Heart Fail Rev 2018;23:191–208.

11. Freeman JV, Varosy P, Price MJ, et al. The NCDR Left Atrial Appendage Occlusion Registry. J Am Coll Cardiol 2020;75:1503–1518.

12. Doshi SK, Sadhu A, Horton RP, et al. Primary outcome evaluation of a next generation left atrial appendage closure device: the PINNACLE FLX trial. Heart Rhythm 2020;17:1208–1211.

13. Vuddanda VLK, Turagam MK, Umale NA, et al. Incidence and causes of in-hospital outcomes and 30-day readmissions after percutaneous left atrial appendage closure: a US nationwide retrospective cohort study using claims data. Heart Rhythm 2020;17:374–382.

14. Centers for Medicare & Medicaid Services. Percutaneous left atrial appendage closure (LAAC). https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/LAAC. Accessed December 21, 2020.